The research referred to in the post - The future of biopharma: Reimagining business models in 2040 - can be accessed here.
Tom Yang is a principal at Deloitte Consulting and assists biopharma and biotech executives deliver growth strategies that adapt to the ever-evolving life sciences and health care landscape. He has worked extensively with clients to develop and commercialize breakthrough products in oncology, immunology, and liver disease.
Sonal Shah is a senior manager with the Deloitte Center for Health Solutions within Deloitte Services LP and leads the center’s life sciences research. Through her research, she helps inform Deloitte’s health care, life sciences, and government clients about emerging trends, challenges, and opportunities. Prior to Deloitte, Sonal worked in the biopharma industry.
Christine Chang, MPH, is a research manager with the Deloitte Center for Health Solutions, Deloitte Services LP. She conducts primary and secondary research and analysis on emerging trends, challenges, and opportunities within the health care system. She supports Deloitte’s Life Sciences and Health Care practice across all sectors and has written on topics including innovation, value-based care, and emerging technologies.
Armed with insights on where to play and how to win, biopharma leaders should then develop strategies to take advantage of the opportunities that emerge in a future built around prevention, early detection, and personalized therapies.